SWM
ANIK icon

SeaCrest Wealth Management’s Anika Therapeutics ANIK Stock Holding History

SeaCrest Wealth Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-100
Closed -$5K – 2194
2018
Q1 		$5K Hold
100
– – ﹤0.01% 1771
2017
Q4 		$5K Buy
+100
New +$5.54K ﹤0.01% 1784

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

SeaCrest Wealth Management's ANIK Position: Q2 2018 in Review

SeaCrest Wealth Management sold out of Anika Therapeutics (ANIK) in Q2 2018, closing a stake of 100 shares — an estimated $5K sold.

SeaCrest Wealth Management first reported a position in ANIK in Q4 2017 and held it in 2 quarters. The position peaked at $5K in Q1 2018. 170 funds tracked by Wall St. Rank hold ANIK as of Q2 2018.

  • SeaCrest Wealth Management reported no remaining Anika Therapeutics position as of Q2 2018 after selling out during the quarter.
  • SeaCrest Wealth Management sold 100 Anika Therapeutics shares in Q2 2018, an estimated $5K.
  • SeaCrest Wealth Management first reported a position in Anika Therapeutics in Q4 2017 and held it in 2 quarters.
  • SeaCrest Wealth Management's Anika Therapeutics position peaked at $5K in Q1 2018.
  • 170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2018.

Based on SeaCrest Wealth Management's 13F filing for Q2 2018, filed 3 Aug 2018.